CN Bio launches PhysioMimix Bioavailability assay kit Human 18

CN Bio, a leading provider of organ-on-a-chip systems and solutions that accelerate drug discovery and development workflows, has launched its PhysioMimix^® Bioavailability assay kit: Human 18. Harnessing the capabilities of the PhysioMimix Multi-organ System, the kit enhances lead optimization and preclinical testing pipelines, providing an all-in-one solution to generate predictive insights into human oral bioavailability, and better inform lead candidate selection.

The kit has been developed following the successful launch of CN Bio’s PhysioMimix Bioavailability assay into its ADME Contract Research Service offerings in January 2024, in response to market demand for a novel approach to address the limitations of traditional methods.

The company has refined the assay into an easy-to-use kit format, enabling customers to rapidly onboard and recreate the assay in their own labs. The Bioavailability assay kit: Human 18 is optimized for use with the company’s PhysioMimix^® Multi-organ System, bridging the gap between in vitro and in vivo studies to enable accurate and predictive profiling of human oral drug bioavailability earlier in the drug development process. It enables researchers to select and progress only the most promising therapeutic candidates, better inform in vivo study design, and minimize the number of animals required.

CN Bio’s Bioavailability assay harnesses the company’s gut/liver-on-a-chip model (also known as a gut/liver microphysiological system), developed in partnership with Altis Biosystems. Leveraging the organ-specific expertise of each company, it fluidically links two human-derived and highly characterized models: Altis Biosystems’ RepliGut^® Jejunum model and CN Bio’s FDA-recognized PhysioMimix Liver-on-a-chip, into one complete system.

This dual-organ model accurately recapitulates key processes that determine bioavailability, including intestinal absorption, intestinal metabolism and hepatic clearance. It also enables users to simulate both intravenous and oral dosing routes, by assessing the models separately or as a combined system.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>